JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Taha Mohamed, Hossam | |
| dc.contributor.author | El-Ghonaimy, Eslam A | |
| dc.contributor.author | El-Shinawi, Mohamed | |
| dc.contributor.author | Hosney, Mohamed | |
| dc.contributor.author | Götte, Martin | |
| dc.contributor.author | Woodward, Wendy A | |
| dc.contributor.author | El-Mamlouk, Tahani | |
| dc.contributor.author | Mostafa Mohamed, Mona | |
| dc.date.accessioned | 2020-06-20T08:32:26Z | |
| dc.date.available | 2020-06-20T08:32:26Z | |
| dc.date.issued | 8/15/2020 | |
| dc.identifier.citation | Anderson, W.F., Chu, K.C., Chang, S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: Distinct clinicopathologic entities? (2003) Journal of Clinical Oncology, 21 (12), pp. 2254-2259. Cited 118 times. doi: 10.1200/JCO.2003.07.082 View at Publisher 2 Arefieva, T.I., Kukhtina, N.B., Antonova, O.A., Krasnikova, T.L. MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades (2005) Cytokine, 31 (6), pp. 439-446. Cited 52 times. doi: 10.1016/j.cyto.2005.06.016 View at Publisher 3 Bakst, R.L., Xiong, H., Chen, C.-H., Deborde, S., Lyubchik, A., Zhou, Y., He, S., (...), Wong, R.J. Inflammatory monocytes promote perineural invasion via CCL2-mediated recruitment and cathepsin B expression (Open Access) (2017) Cancer Research, 77 (22), art. no. Y, pp. 6400-6414. Cited 12 times. http://cancerres.aacrjournals.org//content/canres/77/22/6400.full.pdf doi: 10.1158/0008-5472.CAN-17-1612 View at Publisher 4 Breznik, B., Motaln, H., Turnšek, T.L. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours (Open Access) (2017) Biological Chemistry, 398 (7), pp. 709-719. Cited 14 times. http://www.reference-global.com/toc/bchm/current doi: 10.1515/hsz-2016-0283 View at Publisher 5 Dutta, P., Sarkissyan, M., Paico, K., Wu, Y., Vadgama, J.V. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis (Open Access) (2018) Breast Cancer Research and Treatment, 170 (3), pp. 477-486. Cited 18 times. www.wkap.nl/journalhome.htm/0167-6806 doi: 10.1007/s10549-018-4760-8 View at Publisher 6 Fouad, T.M., Barrera, A.M.G., Reuben, J.M., Lucci, A., Woodward, W.A., Stauder, M.C., Lim, B., (...), Ueno, N.T. Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system (2017) The Lancet Oncology, 18 (4), pp. e228-e232. Cited 21 times. http://www.journals.elsevier.com/the-lancet-oncology/ doi: 10.1016/S1470-2045(17)30192-4 View at Publisher 7 Freund, A., Jolivel, V., Durand, S., Kersual, N., Chalbos, D., Chavey, C., Vignon, F., (...), Lazennec, G. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells (Open Access) (2004) Oncogene, 23 (36), pp. 6105-6114. Cited 87 times. doi: 10.1038/sj.onc.1207815 View at Publisher 8 Funakoshi, Y., Wang, Y., Semba, T., Masuda, H., Hout, D., Ueno, N.T., Wang, X. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype (Open Access) (2019) PLoS ONE, 14 (9), art. no. e0222336. https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0222336&type=printable doi: 10.1371/journal.pone.0222336 View at Publisher 9 Hartman, Z.C., Poage, G.M., Den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., (...), Brown, P.H. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8 (Open Access) (2013) Cancer Research, 73 (11), pp. 3470-3480. Cited 194 times. http://cancerres.aacrjournals.org/content/73/11/3470.full.pdf+html doi: 10.1158/0008-5472.CAN-12-4524-T View at Publisher 10 Huber, M.C., Mall, R., Braselmann, H., Feuchtinger, A., Molatore, S., Lindner, K., Walch, A., (...), Aubele, M. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R (Open Access) (2016) BMC Cancer, 16 (1), art. no. 615. Cited 10 times. http://www.biomedcentral.com/bmccancer/ doi: 10.1186/s12885-016-2663-9 View at Publisher 11 Hwang, C.S., Prieto, V.G., Diwan, A.H., Lizee, G., Ellerhorst, J.A., Ekmekcioglu, S., Liu, P., (...), Kim, K.B. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment (2008) Melanoma Research, 18 (4), pp. 241-245. Cited 7 times. doi: 10.1097/CMR.0b013e3283046146 View at Publisher 12 Jane, D.T., Morvay, L., DaSilva, L., Cavallo-Medved, D., Sloane, B.F., Dufresne, M.J. Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH (2006) Biological Chemistry, 387 (2), pp. 223-234. Cited 29 times. doi: 10.1515/BC.2006.030 View at Publisher 13 Kertmen, N., Babacan, T., Keskin, O., Solak, M., Sarici, F., Akin, S., Arik, Z., (...), Altundag, K. Molecular subtypes in patients with inflammatory breast cancer; A single center experience (2015) Journal of B.U.ON., 20 (1), pp. 35-39. Cited 7 times. http://bu-on.org/jbuon/ 14 Lacerda, L., Reddy, J.P., Liu, D., Larson, R., Li, L., Masuda, H., Brewer, T., (...), Woodward, W.A. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation (Open Access) (2014) Stem Cells Translational Medicine, 3 (7), pp. 849-856. Cited 39 times. http://stemcellstm.alphamedpress.org/content/3/7/849.full.pdf+html doi: 10.5966/sctm.2013-0204 View at Publisher 15 Lee, M., Fridman, R., Mobashery, S. Extracellular proteases as targets for treatment of cancer metastases (2004) Chemical Society Reviews, 33 (7), pp. 401-409. Cited 66 times. doi: 10.1039/b209224g View at Publisher 16 Lesslie, D.P., Summy, J.M., Parikh, N.U., Fan, F., Trevino, J.G., Sawyer, T.K., Metcalf, C.A., (...), Gallick, G.E. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases (Open Access) (2006) British Journal of Cancer, 94 (11), pp. 1710-1717. Cited 97 times. doi: 10.1038/sj.bjc.6603143 View at Publisher 17 Liedtke, C., Mazouni, C., Hess, K.R., André, F., Tordai, A., Mejia, J.A., Symmans, W.F., (...), Pusztai, L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer (2008) Journal of Clinical Oncology, 26 (8), pp. 1275-1281. Cited 1557 times. http://jco.ascopubs.org/cgi/reprint/26/8/1275 doi: 10.1200/JCO.2007.14.4147 View at Publisher 18 Lieu, C., Kopetz, S. The Src family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy (2010) Clinical Colorectal Cancer, 9 (2), pp. 89-94. Cited 43 times. http://www.journals.elsevier.com/clinical-colorectal-cancer doi: 10.3816/CCC.2010.n.012 View at Publisher 19 Lim, B., Woodward, W.A., Wang, X., Reuben, J.M., Ueno, N.T. Inflammatory breast cancer biology: the tumour microenvironment is key (2018) Nature Reviews Cancer, 18 (8), pp. 485-499. Cited 29 times. http://www.nature.com/cancer/ doi: 10.1038/s41568-018-0010-y View at Publisher 20 Lin, C.-C., Chen, K.-B., Tsai, C.-H., Tsai, F.-J., Huang, C.-Y., Tang, C.-H., Yang, J.-S., (...), Chung, J.-G. Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-κB signaling pathways (2019) Journal of Food Biochemistry, 43 (7), art. no. e12902. Cited 13 times. http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1745-4514 doi: 10.1111/jfbc.12902 View at Publisher 21 Liu, C.-J., Kuo, F.-C., Wang, C.-L., Kuo, C.-H., Wang, S.S.W., Chen, C.-Y., Huang, Y.-B., (...), Wu, D.-C. Suppression of IL-8-Src signalling axis by 17β-estradiol inhibits human mesenchymal stem cells-mediated gastric cancer invasion (Open Access) (2016) Journal of Cellular and Molecular Medicine, 20 (5), pp. 962-972. Cited 16 times. http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934 doi: 10.1111/jcmm.12786 View at Publisher 22 Mayer, E.L., Krop, I.E. Advances in targeting Src in the treatment of breast cancer and other solid malignancies (Open Access) (2010) Clinical Cancer Research, 16 (14), pp. 3526-3532. Cited 129 times. http://clincancerres.aacrjournals.org/content/16/14/3526.full.pdf+html doi: 10.1158/1078-0432.CCR-09-1834 View at Publisher 23 Mohamed, M.M., Sloane, B.F. Cysteine cathepsins: Multifunctional enzymes in cancer (2006) Nature Reviews Cancer, 6 (10), pp. 764-775. Cited 884 times. doi: 10.1038/nrc1949 View at Publisher 24 Mohamed, M.M. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway (2012) Cell Commun. Signal, 10, p. 3. Cited 24 times. 25 Mohamed, M.M., Cavallo-Medved, D., Sloane, B.F. Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer (2008) Biological Chemistry, 389 (8), pp. 1117-1121. Cited 13 times. doi: 10.1515/BC.2008.117 View at Publisher 26 Mohamed, M.M., El-Ghonaimy, E.A., Nouh, M.A., Schneider, R.J., Sloane, B.F., El-Shinawi, M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties (2014) International Journal of Biochemistry and Cell Biology, 46 (1), pp. 138-147. Cited 56 times. doi: 10.1016/j.biocel.2013.11.015 View at Publisher 27 Moin, K., Day, N.A., Sameni, M., Hasnain, S., Hirama, T., Sloane, B.F. Human tumour cathepsin B. Comparison with normal liver cathepsin B (1992) Biochemical Journal, 285 (2), pp. 427-434. Cited 102 times. doi: 10.1042/bj2850427 View at Publisher 28 Nouh, M.A., Mohamed, M.M., El-Shinawi, M., Shaalan, M.A., Cavallo-Medved, D., Khaled, H.M., Sloane, B.F. Cathepsin b: A potential prognostic marker for inflammatory breast cancer (Open Access) (2011) Journal of Translational Medicine, 9, art. no. 1. Cited 82 times. http://www.translational-medicine.com/content/9/1/1 doi: 10.1186/1479-5876-9-1 View at Publisher 29 Onion, D., Argent, R.H., Reece-Smith, A.M., Craze, M.L., Pineda, R.G., Clarke, P.A., Ratan, H.L., (...), Grabowska, A.M. 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors (Open Access) (2016) Molecular Cancer Therapeutics, 15 (4), pp. 753-763. Cited 14 times. http://mct.aacrjournals.org/content/15/4/753.full.pdf+html doi: 10.1158/1535-7163.MCT-15-0598 View at Publisher 30 Park, K.-Y., Li, G., Platt, M.O. Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk (Open Access) (2015) Scientific Reports, 5, art. no. 13855. Cited 16 times. www.nature.com/srep/index.html doi: 10.1038/srep13855 View at Publisher 31 Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. (2001) Nucleic acids research, 29 (9), p. e45. Cited 20835 times. 32 Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., (...), Pollard, J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis (2011) Nature, 475 (7355), pp. 222-225. Cited 1226 times. doi: 10.1038/nature10138 View at Publisher 33 Sameni, M., Moin, K., Sloane, B.F. Imaging proteolysis by living human breast cancer cells (2000) Neoplasia, 2 (6), pp. 496-504. Cited 133 times. View at Publisher 34 Sameni, M., Anbalagan, A., Olive, M.B., Moin, K., Mattingly, R.R., Sloane, B.F. MAME models for 4D live-cell imaging of tumor: Microenvironment interactions that impact malignant progression (2012) Journal of Visualized Experiments, (60), art. no. e3661. Cited 33 times. http://www.jove.com/resources/pubmedgen/default.aspx?PDF=&ID=3661 doi: 10.3791/3661 View at Publisher 35 Schittenhelm, M.M., Shiraga, S., Schroeder, A., Corbin, A.S., Griffith, D., Lee, F.Y., Bokemeyer, C., (...), Heinrich, M.C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies (Open Access) (2006) Cancer Research, 66 (1), pp. 473-481. Cited 405 times. doi: 10.1158/0008-5472.CAN-05-2050 View at Publisher 36 Schlichting, J.A., Soliman, A.S., Schairer, C., Schottenfeld, D., Merajver, S.D. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008 (2012) Breast Cancer Research and Treatment, 134 (3), pp. 1257-1268. Cited 25 times. doi: 10.1007/s10549-012-2133-2 View at Publisher 37 Sevenich, L., Joyce, J.A. Pericellular proteolysis in cancer (Open Access) (2014) Genes and Development, 28 (21), pp. 2331-2347. Cited 80 times. http://genesdev.cshlp.org/content/28/21/2331.full.pdf doi: 10.1101/gad.250647.114 View at Publisher 38 Victor, B.C., Anbalagan, A., Mohamed, M.M., Sloane, B.F., Cavallo-Medved, D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion (Open Access) (2011) Breast Cancer Research, 13 (6), art. no. R115. Cited 70 times. http://breast-cancer-research.com/content/13/6/R115 doi: 10.1186/bcr3058 View at Publisher 39 Waugh, D.J.J., Wilson, C. The interleukin-8 pathway in cancer (Open Access) (2008) Clinical Cancer Research, 14 (21), pp. 6735-6741. Cited 1195 times. http://clincancerres.aacrjournals.org/cgi/reprint/14/21/6735 doi: 10.1158/1078-0432.CCR-07-4843 View at Publisher 40 Wheeler, D.L., Iida, M., Dunn, E.F. The role of Src in solid tumors (2009) Oncologist, 14 (7), pp. 667-678. Cited 195 times. http://theoncologist.alphamedpress.org/cgi/reprint/14/7/667 doi: 10.1634/theoncologist.2009-0009 View at Publisher 41 Xie, K. Interleukin-8 and human cancer biology (2001) Cytokine and Growth Factor Reviews, 12 (4), pp. 375-391. Cited 543 times. doi: 10.1016/S1359-6101(01)00016-8 View at Publisher 42 Yadav, B.S., Sharma, S.C., Chanana, P., Jhamb, S. Systemic treatment strategies for triple-negative breast cancer (Open Access) (2014) World Journal of Clinical Oncology, 5 (2), pp. 125-133. Cited 73 times. http://www.wjgnet.com/2218-4333/ejournals/WJCOv5i2.pdf doi: 10.5306/wjco.v5.i2.125 View at Publisher 43 Yao, M., Fang, W., Smart, C., Hu, Q., Huang, S., Alvarez, N., Fields, P., (...), Cheng, N. CCR2 chemokine receptors enhance growth and cell-cycle progression of breast cancer cells through SRC and PKC activation (Open Access) (2019) Molecular Cancer Research, 17 (2), pp. 604-617. Cited 9 times. http://mcr.aacrjournals.org/content/17/2/604.full-text.pdf doi: 10.1158/1541-7786.MCR-18-0750 View at Publisher 44 Zhang, H., Fu, T., Mcgettigan, S., Kumar, S., Liu, S., Speicher, D., Schuchter, L., (...), Xu, X. IL8 and cathepsin B as melanoma serum biomarkers (Open Access) (2011) International Journal of Molecular Sciences, 12 (3), pp. 1505-1518. Cited 33 times. http://www.mdpi.com/1422-0067/12/3/1505/pdf doi: 10.3390/ijms12031505 | en_US |
| dc.identifier.issn | 0041008X | |
| dc.identifier.other | https://doi.org/10.1016/j.taap.2020.115092 | |
| dc.identifier.uri | https://t.ly/KChk | |
| dc.description | Scopus | en_US |
| dc.description.abstract | Inflammatory breast cancer (IBC) is a highly metastatic and lethal breast cancer. As many as 25–30% of IBCs are triple negative (TN) and associated with low survival rates and poor prognosis. We found that the microenvironment of IBC is characterized by high infiltration of tumor associated macrophages (TAMs) and by over-expression of the cysteine protease cathepsin B (CTSB). TAMs in IBC secrete high levels of the cytokines interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1/CCL2) compared to non-IBC patients. Herein, we tested the roles of IL-8 and MCP-1/CCL2 in modulating proteolytic activity and invasiveness of TN-non-IBC as compared to TN-IBC and addressed the underlying molecular mechanism(s) for both cytokines. Quantitative real time PCR results showed that IL-8 and MCP-1/CCL2 were significantly overexpressed in tissues of TN-IBCs. IL-8 and MCP-1/CCL2 induced CTSB expression and activity of the p-Src and p-Erk1/2 signaling pathways relevant for invasion and metastasis in TN-non-IBC, HCC70 cells and TN-IBC, SUM149 cells. Dasatinib, an inhibitor of p-Src, and U0126, an inhibitor of p-Erk1/2, down-regulated invasion and expression of CTSB by HCC70 and SUM149 cells, a mechanism that is reversed by IL-8 and MCP-1/CCL2. Our study shows that targeting the cytokines IL-8 and MCP-1/CCL2 and associated signaling molecules may represent a promising therapeutic strategy in TN-IBC patients | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Academic Press Inc. | en_US |
| dc.relation.ispartofseries | Toxicology and Applied Pharmacology;Volume 401, 15 August 2020, Article number 115092 | |
| dc.subject | Inflammatory Breast Cancer | en_US |
| dc.subject | Cathepsin B | en_US |
| dc.subject | IL-8 | en_US |
| dc.subject | MCP-1/CCL2 | en_US |
| dc.subject | Dasatinib | en_US |
| dc.subject | U0126 | en_US |
| dc.title | IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2 | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1016/j.taap.2020.115092 | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
